Risks and benefits of glycoprotein IIb/IIIa antagonists in acute coronary syndrome

Annals of Pharmacotherapy

Volumn 35, Issue 4, 2001, Pages 472-479

  Latour Perez J ^a  

^a Universitario de Elche FISABIO   (Spain)

Author keywords

Angina; Myocardial infarction; Platelet aggregation inhibitors; Platelet glycoprotein GPIIb IIIa complex antagonists

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LAMIFIBAN; TICLOPIDINE; TIROFIBAN;

ARTICLE; BLEEDING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0035088793     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.10151     Document Type: Article

References (41)

1. Effects of integrilin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial
2. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study
3. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina
4. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
5. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction
6. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
7. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
8. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease
9. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
10. Meta-analysis in clinical trials
11. A note on graphical presentation estimated odds ratios from several clinical trials
12. Operating characteristics of a rank correlation test for publication bias
13. Bias in meta-analysis detected by a simple graphical test
14. An assessment of clinically useful measures of the consequences of treatment
15. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes
16. Adjusting the number needed to treat. Incorporating adjustments for utility and timing of benefits and harms
17. Users' guides to the medical literature. IX. A method for grading health care recommendations
18. Users' guides to the medical literature. XVI. How to use a treatment recommendation
19. Making decisions about antithromboric therapy in heart disease. Decision analytic and cost-effectiveness issues
20. The Beaver Dam Health Outcomes Study: Initial catalog of health-state quality factors
21. Dollars may not buy as many QALYs as we think: A problem with defining quality-of-life adjustments
22. Bleeding complications with platelet glycoprotein IIb/IIIa receptor antagonists
23. Numbers needed to treat derived from meta-analyses - Sometimes informative, usually misleading
24. Clinical predictors of in-hospital prognosis in unstable angina: ECLA 3
25. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban
26. Age and outcome after acute coronary syndromes without persistent ST-segment elevation
27. Users' guides to the medical literature. XIX. Applying clinical trials results. B. Guidelines for determining whether a drug is exerting (more than) a class effect
28. Tirofiban
29. Quality of life six months after myocardial infarction treated with thrombolytic therapy
30. Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction
31. Users' guides to the medical literature. XX. Integrating research evidence with the care of the individual patient
32. Optimal treatment of patients with acute coronary syndromes and non-ST-elevation myocardial infarction
33. A classification of unstable angina revisited
34. 1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)
35. Economic assessment of tirofiban in the management of acute coronary syndromes in the hospital setting. An analysis based on the PRISM PLUS trial
36. Economic issues in glycoprotein IIb/IIIa receptor therapy
37. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations
38. A comparison of low-molecular-weight heparin with unfractioned heparin for unstable coronary artery disease
39. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results from the Thrombolysis in Myocardial Infarction (TIMI) 11B trial
40. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction TIMI 11B-ESSENCE meta-analysis